ANP (Atrial Natriuretic Peptide) vs MGF (Mechano Growth Factor)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
ANP (Atrial Natriuretic Peptide)
ANP is a cardiac hormone released by atrial myocytes in response to stretch. It promotes natriuresis, diuresis, and vasodilation, playing key roles in blood pressure and fluid regulation.
Full details →MGF (Mechano Growth Factor)
MGF (Mechano Growth Factor) is a splice variant of IGF-1 that is produced locally in muscle tissue in response to mechanical stress. The non-PEGylated form has a very short half-life.
Full details →Side-by-Side Comparison
| Aspect | ANP (Atrial Natriuretic Peptide) | MGF (Mechano Growth Factor) |
|---|---|---|
| Dose Range | 25 mcg–100 mcg | 400 mcg–1.2 mg |
| Frequency | 1x daily | Less than daily |
| Cycle Length | 1–4 weeks | 4–6 weeks |
| Route | subcutaneous | intramuscular |
| Mechanism | Binds to natriuretic peptide receptors (NPR-A) to activate guanylyl cyclase, producing cGMP. This leads to vasodilation, increased kidney filtration, and inhibition of the renin-angiotensin-aldosterone system. | Activates muscle satellite cells (stem cells) and promotes their proliferation without differentiation, priming them for fusion with existing muscle fibers during repair and growth. |
| Typical Dosage | Clinical use: Carperitide (recombinant ANP) used in Japan for acute heart failure at 0.1mcg/kg/min IV infusion. | Due to extremely short half-life (minutes), typical protocols use 100-200mcg injected directly into target muscles immediately post-workout. |
| Administration | Intravenous infusion only for clinical applications. Short half-life (~2 minutes) requires continuous administration. | Intramuscular injection into trained muscles within minutes of workout completion. Must be used immediately after reconstitution due to instability. |
| Side Effects | Hypotension (dose-limiting), headache, nausea, and potential arrhythmias at high doses. | Injection site soreness, potential hypoglycemia, localized swelling. Short half-life limits systemic effects. |
| Best For |
What They Have in Common
ANP (Atrial Natriuretic Peptide), MGF (Mechano Growth Factor) are both commonly used for:
Key Differences
Unique to MGF (Mechano Growth Factor):
Which Has Stronger Evidence?
| Goal | ANP (Atrial Natriuretic Peptide) | MGF (Mechano Growth Factor) |
|---|---|---|
| Recovery & Healing | medium | medium |
Key Studies
ANP (Atrial Natriuretic Peptide)
- Atrial natriuretic peptide (ANP) modulates stress-induced autophagy in endothelial cells.
Biochimica et biophysica acta. Molecular cell research, 2025
- C-atrial natriuretic peptide (ANP)(4-23) attenuates renal fibrosis in deoxycorticosterone-acetate-salt hypertensive mice.
Experimental cell research, 2023
- Novel ANP (Atrial Natriuretic Peptide)-Based Therapy for Hypertension: The Promising Role of a Disease Mechanism Targeted Approach.
Hypertension (Dallas, Tex. : 1979), 2021
MGF (Mechano Growth Factor)
- The role of mechano growth factor in chondrocytes and cartilage defects: a concise review.
Acta biochimica et biophysica Sinica, 2023
- Pretreatment with mechano growth factor E peptide attenuates osteoarthritis through improving cell proliferation and extracellular matrix synthesis in chondrocytes under severe hypoxia.
International immunopharmacology, 2021
- Mechano growth factor interacts with nucleolin to protect against cisplatin-induced neurotoxicity.
Experimental neurology, 2020
Ready to Learn More?
Looking for trusted sources?